![]() In future, the sensitivity and specificity of PointMan™ may be exploited to provide screening and monitoring tests for the early detection of cancer from peripheral blood samples and other non-tumour sources of cancer DNA.At Thoughtworks, we've long been fans of open-source software, popularized in part by Eric Raymond's famous essay "The Cathedral and the Bazaar." Open-source software improves developer mobility and crowdsources both bug fixes and innovation. Deployment of high-sensitivity detection of low frequency alleles has to-date been limited to high capital-cost equipment, based within clinical research laboratories. If you have heterogeneous samples, rare samples where repeat testing for multiple mutations at a target codon is not an option, or non-tumour sources of cancer DNA such as peripheral blood samples, urine or sputum, then PointMan™ is your assay of choice. PointMan™ allows the detection of point mutated DNA down to 0.01% against a background of the wild-type, effectively eliminating the risk to pathologists and researcher scientists that mutation rates in their tumour biopsy samples fall below detectable levels. 360 Genomics’ ultra-sensitive PointMan™ enrichment technology can enrich samples for all mutations at a target position, using a simple to use reagent set that works on the generality of thermocycler platforms. The Company has a pipeline of assays for the detection of mutations in key oncogenes at sensitivities far greater than existing chemistry platforms, and at a cost that is compatible with near patient testing and patient screening programs. The system consists of a wristband for each hospital patient, a smart container system electro-mechanical lock for placing the bags of blood, and management software that unifies the whole of transfusion safety, providing control and the proper management of all containers in the hospital.ģ60 Genomics develops diagnostic technologies to ensure the most timely and appropriate therapy for cancer patients. In response to this need worldwide Veridentia marketed under the brand VerIDhemos, RFID-based technology to ensure proper procedure on blood transfusions in hospitals, avoiding any impact transfusion. Currently 1 of 12,000 of these patients have a severe transfusion incidence due to preventable errors, and about 10-15 of these patients per year may lead to a fatal situation due to the administration of the wrong blood. In Spain alone, 500,000 patients receive the 1.4 million units of blood that are extracted in Spain, at least once a year. Today it is recognized that there is a high risk to the health of patients in 1 of every 12,000 transfusions. and Canada, among other, there is still a high number of transfusion incidents, many of them serious, which are due mostly to human error. As is clear from the data available from the international scientific literature, as well as data from different systems haemovigilance (tracking system incidents in blood transfusions), coordinated by the various European governments, U.S. Veridentia, founded in 2007, and selling since 2009, focus on security systems tranfusional. ![]() Together with Sahlgrenska University Hospital we have performed an initial proof of concept that successfully verified the functionality of a manually handled prototype. BaxID uses the genetic fingerprint of bacteria, compare it to a unique and comprehensive database and returns a complete profile of the analyzed bacteria to the client in a user friendly format. The accessible market in the 6 countries that we initially focus on is estimated to 6000 mSEK/year. A 30 % reduction of the time patients spend at the Swedish hospitals would save about 200 mSEK/year. This enables the doctors to give patients correct treatment much earlier which will improve patient recovery and survival. BaxID is a decision support system for substantially faster and more efficient analysis of patient samples. We are developing a new technology for determination and monitoring of antibiotic resistant bacteria that will be offered to bacteriology laboratories/hospitals worldwide. ![]() New technology for determination of antibiotic resistant bacteria.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |